Cargando…
Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease
Peptides and their mimetics are increasingly recognised as drug-like molecules, particularly for intracellular protein-protein interactions too large for inhibition by small molecules, and inaccessible to larger biologics. In the past two decades, evidence associating the misfolding and aggregation...
Autores principales: | Allen, Scott G., Meade, Richard M., White Stenner, Lucy L., Mason, Jody M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633918/ https://www.ncbi.nlm.nih.gov/pubmed/37940962 http://dx.doi.org/10.1186/s13024-023-00675-8 |
Ejemplares similares
-
Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles
por: Meade, Richard M., et al.
Publicado: (2019) -
Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation
por: Torpey, James H., et al.
Publicado: (2020) -
Library-Derived Peptide Aggregation Modulators of
Parkinson’s Disease Early-Onset α-Synuclein Variants
por: Watt, Kathryn J. C., et al.
Publicado: (2022) -
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
por: Fields, Carroll Rutherford, et al.
Publicado: (2019) -
Parkinson’s Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation
por: Zoey, Fong LaiGuan, et al.
Publicado: (2021)